Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study
Figure 3
Mouse MOG homologue of RTL1000 treats EAE in DR2 transgenic mice. HLA-DR2 mice were immunized with mouse (m)MOG-35-55 peptide + CFA + Ptx to induce EAE and were treated IV with a single dose of 100 μg of the mouse (m)MOG homologue of RTL1000 (DR2/mMOG-35-55 peptide) or buffer at onset of clinical signs of EAE (indicated as Day 0, corresponding to ~Day 10 after immunization). The mice were scored daily for 28 days for clinical signs of EAE ( mice/group). Reduction in daily scores and cumulative disease scores in RTL versus vehicle-treated mice was significant (*; †, resp.). Inset. Dose comparisons in mice versus humans based on body surface area. Note that the 100 μg dose that is highly effective at treating EAE in mice is equivalent to a ~25 mg dose in humans, well within the safe dose range determined in our study. Figure reproduced in part from Offner et al. [23].
